| Q91760395 | A 6-Month, Prospective, Randomized Controlled Trial of Customized Adherence Enhancement Versus Bipolar-Specific Educational Control in Poorly Adherent Individuals With Bipolar Disorder |
| Q48381074 | A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia |
| Q54957701 | A Cross-sectional Analysis of Patterns and Predictors of Medication Adherence in Bipolar Disorder: Single Center Experience from South India. |
| Q39526505 | A Questionnaire-based Study of the Views of Schizophrenia Patients and Psychiatric Healthcare Professionals in Japan about the Side Effects of Clozapine |
| Q34359774 | A computerized self-report symptom distress inventory: for use as a routine clinical interview in schizophrenia |
| Q45283179 | A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation |
| Q99637564 | A multi-center naturalistic study of a newly designed 12-sessions group psychoeducation program for patients with bipolar disorder and their caregivers |
| Q48635203 | A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial |
| Q64901229 | A pilot study evaluating the effectiveness of a medicines education group in a mental health inpatient setting: A UK perspective. |
| Q67522304 | A two-year prospective study of treatment compliance in patients with schizophrenia |
| Q99565116 | Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia |
| Q45246308 | Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. |
| Q33583484 | Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory |
| Q81093739 | An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists |
| Q41889293 | An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia |
| Q40474904 | Antipsychotic Adherence Intervention for Veterans over 40 with Schizophrenia: Results of a Pilot Study. |
| Q41957512 | Antipsychotic agents: efficacy and safety in schizophrenia |
| Q38041979 | Are attitudes towards medication adherence associated with medication adherence behaviours among patients with psychosis? A systematic review and meta analysis |
| Q72012331 | Assessing the side‐effects of antipsychotic drugs: a survey of CPN practice |
| Q42353132 | Assessment of impact of pharmacophilia and pharmacophobia on medication adherence in patients with psychiatric disorders: A cross-sectional study |
| Q33347832 | Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study |
| Q64078212 | Association between Therapeutic Alliance and Adherence in Outpatient Schizophrenia Patients |
| Q86978635 | Attitude towards second-generation antipsychotics among patients with schizophrenia and their relatives |
| Q47356859 | Attitudes and experience of youth and their parents with psychiatric medication and relationship to self-reported adherence |
| Q42121124 | Attitudes toward Medication and Reasons for Non-Compliance in Patients with Schizophrenia |
| Q37423697 | Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models |
| Q51900453 | Attitudes toward psychiatric drug treatment: the experience of being treated. |
| Q33350392 | Attitudes toward psychopharmacology among hospitalized patients from diverse ethno-cultural backgrounds |
| Q41976148 | Attitudes toward psychotropic medications among patients with chronic psychiatric disorders and their family caregivers |
| Q37232256 | Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing |
| Q33908823 | Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications |
| Q46469930 | Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire |
| Q92022422 | Attitudes towards psychopharmacology and psychotherapy in psychiatric patients with and without migration background |
| Q34186152 | Attitudes towards taking Medicine among those patients who either received Olanzapine or First Generation Antipsychotic Agents |
| Q34144373 | Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence |
| Q38462899 | Beliefs about medications predict adherence to antidepressants in older adults. |
| Q34864049 | Bipolar Disorder Patients Follow-up (BDPF): methods and materials. |
| Q73299939 | CYP2D6 mutations and therapeutic outcome in schizophrenic patients |
| Q37945332 | Can patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks? |
| Q24193108 | Cannabis and schizophrenia |
| Q46528704 | Clinical experiences and clinical trials. |
| Q36345110 | Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: the PERSEO (psychiatric emergency study and epidemiology) survey |
| Q34925861 | Clinical management and burden of bipolar disorder: a multinational longitudinal study (WAVE-bd study) |
| Q24236422 | Clozapine versus other atypical antipsychotics for schizophrenia |
| Q50641778 | Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. |
| Q24246180 | Cognitive behaviour therapy for schizophrenia |
| Q28204176 | Cognitive behaviour therapy for schizophrenia |
| Q60961366 | Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia |
| Q40806493 | Cognitive predictors of adherence to malaria prophylaxis regimens on return from a malarious region: a prospective study. |
| Q47721820 | Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia |
| Q33995256 | Collaborative care for patients with bipolar disorder: a randomised controlled trial |
| Q37224567 | Combination therapy or monotherapy for the depressed type of schizoaffective disorder. |
| Q34833550 | Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study |
| Q38016230 | Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? |
| Q53519349 | Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. |
| Q92284981 | Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia |
| Q36102104 | Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China |
| Q42131509 | Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia |
| Q38466049 | Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects |
| Q24244947 | Compliance therapy for schizophrenia |
| Q36597242 | Compliance therapy in psychotic patients: randomised controlled trial |
| Q36274868 | Compliance therapy: a randomised controlled trial in schizophrenia |
| Q74802405 | Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight |
| Q34632976 | Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study |
| Q39490151 | Connection between self-stigma, adherence to treatment, and discontinuation of medication |
| Q39231117 | Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. |
| Q91576471 | Cost-utility analysis of curative and maintenance repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant unipolar depression: a randomized controlled trial protocol |
| Q37137005 | Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia |
| Q37011447 | Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability |
| Q35906816 | Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life |
| Q36481418 | Defining and assessing adherence to oral antipsychotics: a review of the literature |
| Q44594822 | Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR). |
| Q37589461 | Design and Methodology of the Korean Early Psychosis Cohort Study |
| Q57453024 | Determinants of suboptimal medication adherence in patients with a major depressive episode |
| Q40301719 | Developing a measure of medication-related quality of life for people with polypharmacy |
| Q64060895 | Development and validation of the Patient's Health Belief Questionnaire on Psychiatric Treatment |
| Q49120111 | Development of a health screening clinic |
| Q36211700 | Development of the My Medicines and Me (M3Q) side effect questionnaire for mental health patients: a qualitative study |
| Q33619879 | Development of the treatment attitudes questionnaire in bipolar disorder |
| Q36621023 | Does change in cannabis use in established psychosis affect clinical outcome? |
| Q92069819 | Does psychoeducation influence carers' attitudes to treatment of schizophrenia? |
| Q91632734 | Drug Attitude, Insight, and Patient's Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey |
| Q33685476 | Drug attitude and adherence to anti-glaucoma medication. |
| Q74630802 | Drug maintenance treatment compliance and its correlation with the clinical picture and course of schizophrenia |
| Q73466892 | Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology |
| Q28550045 | Effect of a Multi-Dimensional and Inter-Sectoral Intervention on the Adherence of Psychiatric Patients |
| Q40785183 | Effect of a system-oriented intervention on compliance problems in schizophrenia: a pragmatic controlled trial |
| Q64114503 | Effectiveness and cost-effectiveness of a multicomponent intervention to improve medication adherence in people with depressive disorders - MAPDep: a study protocol for a cluster randomized controlled trial |
| Q42376209 | Effects of Group Cognitive-Behavioral Therapy in Young Patients in the Early Stage of Psychosis |
| Q43269341 | Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia |
| Q33612308 | Efficacy of shared decision making on treatment satisfaction for patients with first-admission schizophrenia: study protocol for a randomised controlled trial |
| Q47773155 | Empowerment and its associations in schizophrenia: a cross-sectional study |
| Q39599793 | Evaluation of attitudes towards treatment in adolescents with attention deficit hyperactivity disorder (ADHD). |
| Q48716188 | Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes. |
| Q37623597 | Explaining attitudes and adherence to antipsychotic medication: the development of a process model |
| Q50584707 | Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence. |
| Q40309621 | Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: Factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patients |
| Q41895956 | Factors Affecting Well-being and Socio-occupational Functioning in Schizophrenia Patients Following an Acute Exacerbation: A Hospital Based Observational Study |
| Q50585454 | Factors affecting medication adherence in children receiving outpatient pharmacotherapy and parental adherence. |
| Q58803803 | Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy |
| Q28545127 | Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia |
| Q41629589 | Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy |
| Q37735808 | Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach |
| Q52275725 | Factors influencing relapse in the long-term course of schizophrenia. |
| Q92001788 | Factors that influence patients' attitudes to antipsychotic medication |
| Q36272075 | Feasibility and efficacy of shared decision making for first-admission schizophrenia: a randomized clinical trial |
| Q26471188 | Fluphenazine (oral) versus atypical antipsychotics for schizophrenia |
| Q37658585 | Generic versus branded medicines: An observational study among patients with chronic diseases attending a public hospital outpatient department |
| Q34392459 | Good tolerability equals good results: the patient's perspective |
| Q58231296 | Guidelines for depot antipsychotic treatment in schizophrenia |
| Q39817602 | How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach |
| Q40012236 | Identifying patient-relevant endpoints among individuals with schizophrenia: an application of patient-centered health technology assessment |
| Q57064128 | Identifying the Underlying Factors Associated With Patients' Attitudes Toward Antidepressants: Qualitative and Quantitative Analysis of Patient Drug Reviews |
| Q42669677 | Illness Perceptions in Patients of Schizophrenia: A Preliminary Investigation from Lahore, Pakistan |
| Q35936881 | Impact of atypical antipsychotics on quality of life in patients with schizophrenia |
| Q90984908 | Impact of co-facilitated information programmes on outcomes for service users and family members: the EOLAS programmes (paper 2) |
| Q60472729 | Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients; a randomized controlled trial |
| Q38686206 | Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia |
| Q38071595 | Improving treatment adherence in your patients with schizophrenia: the STAY initiative |
| Q38662474 | Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules. |
| Q74084232 | Indicators of medication compliance in first-episode psychosis |
| Q24193953 | Information and communication technology based prompting for treatment compliance for people with serious mental illness |
| Q24198042 | Information and communication technology in patient education and support for people with schizophrenia |
| Q43561739 | Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China |
| Q34347478 | Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. |
| Q28074062 | Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis |
| Q36526847 | Lay health supporters aided by a mobile phone messaging system to improve care of villagers with schizophrenia in Liuyang, China: protocol for a randomised control trial |
| Q64098086 | Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial |
| Q30835228 | Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort |
| Q92290839 | Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study |
| Q34386881 | Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations |
| Q38115487 | Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective |
| Q84447196 | Long-term effect on outcome of clozapine in chronic therapy-resistant schizophrenic patients |
| Q80131188 | Long-term treatment with long-acting risperidone in Korean patients with schizophrenia |
| Q35115704 | Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. |
| Q37594717 | Measurement of psychiatric treatment adherence |
| Q88884687 | Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China |
| Q35224289 | Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics |
| Q33578485 | Measuring quality of life in patients with schizophrenia |
| Q34363723 | Medication Adherence, Work Performance and Self-Esteem among Psychiatric Patients Attending Psychosocial Rehabilitation Services at Bangalore, India |
| Q26823655 | Medication adherence in schizophrenia |
| Q43453594 | Medication attitudes and beliefs in patients with psychotic and affective disorders on maintenance treatment. |
| Q41363855 | Medication compliance among the seriously mentally ill in a public mental health system |
| Q42701502 | Medication nonadherence among South American patients with schizophrenia. |
| Q61447746 | Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics |
| Q41569037 | Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia |
| Q37580919 | Mobile phone text message reminders of antipsychotic medication: is it time and who should receive them? A cross-sectional trust-wide survey of psychiatric inpatients |
| Q35370011 | Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention |
| Q40874964 | Needs of Patients with Schizophrenia Among an Ethnic Minority Group in Latin America. |
| Q37380093 | Non-Compliance and Related Factors in Patients With Bipolar I Disorder: A Six Month Follow-Up Study |
| Q33857710 | Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies |
| Q51944586 | Obesity as a risk factor for antipsychotic noncompliance. |
| Q24244031 | Olanzapine for schizophrenia |
| Q35839627 | Patient and family attitudes toward schizophrenia treatment |
| Q92001412 | Patient attitudes towards compulsory community treatment orders and advance directives |
| Q40530811 | Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine |
| Q34078005 | Patient compliance with drug therapy in schizophrenia. Economic and clinical issues |
| Q34231565 | Patient perspectives on antipsychotic treatments and their association with clinical outcomes |
| Q46665905 | Patient-centered care in affective, non-affective, and schizoaffective groups: patients' opinions and attitudes |
| Q46408257 | Patients' attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting |
| Q34308680 | Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study |
| Q34677573 | Patients' subjective experiences of antipsychotics: clinical relevance |
| Q46171012 | Perceived racism, medication adherence, and hospital admission in African-Caribbean patients with psychosis in the United Kingdom. |
| Q74363033 | Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia |
| Q93383889 | Predictive validity of the Sidorkiewicz instrument in Spanish: Assessing individual drug adherence in psychiatric patients |
| Q33836094 | Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention |
| Q52017906 | Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. |
| Q60054057 | Predictors of involuntary patients' satisfaction with care: prospective study |
| Q48662934 | Predictors of medication adherence and smoking cessation among smokers under community corrections supervision |
| Q43926986 | Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia |
| Q96305154 | Predictors of pharmacophobia |
| Q34990923 | Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study |
| Q37500112 | Predictors of psychotropic medication adherence among HIV+ individuals living with bipolar disorder |
| Q37661476 | Progress in defining optimal treatment outcome in schizophrenia |
| Q48501173 | Psychiatric outpatients' self-reported adherence versus psychiatrists' impressions on adherence in affective disorders |
| Q93383371 | Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting |
| Q35236962 | Psychosocial interventions and medication adherence in bipolar disorder |
| Q64099413 | Psychotropic medication non-adherence among patients with severe mental disorder attending at Bahir Dar Felege Hiwote Referral hospital, north west Ethiopia, 2017 |
| Q53612819 | Quality of life and self-esteem in working and nonworking persons with mental illness. |
| Q52056573 | Quality of life in chronically mentally ill patients in day treatment. |
| Q37669893 | Quality of life, self-stigma, and hope in schizophrenia spectrum disorders: a cross-sectional study |
| Q35819467 | Quantifying clinical relevance in the treatment of schizophrenia |
| Q79440232 | Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study |
| Q37075939 | Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia |
| Q46258769 | Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives |
| Q31068505 | Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial |
| Q38499772 | Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses |
| Q36067721 | Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication. |
| Q27008464 | Review of depot aripiprazole for schizophrenia |
| Q26801102 | Revisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior |
| Q90236876 | Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later |
| Q42011793 | Risk factors for drug nonadherence in antidepressant-treated patients and implications of pharmacist adherence instructions for adherence improvement |
| Q47722372 | Risk factors for non-adherence to antidepressant treatment in patients with mood disorders |
| Q42691780 | Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication |
| Q53903012 | Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. |
| Q34680925 | Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. |
| Q44466185 | Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study |
| Q35129418 | Shared decision making in psychiatry |
| Q42699034 | Shared decision-making for psychiatric medication: A mixed-methods evaluation of a UK training programme for service users and clinicians. |
| Q41788185 | Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder |
| Q53441831 | Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina, and Venezuela. |
| Q51578149 | Social interaction and drug attitude effectiveness in patients with schizophrenia. |
| Q42600363 | Subjective effects of antipsychotic drugs and their relevance for compliance and remission. |
| Q24801695 | Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study) |
| Q52892785 | Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. |
| Q60646652 | Subjective response to neuroleptic medication: a validation study of the Italian version of the Drug Attitude Inventory (DAI) |
| Q68177319 | Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures |
| Q60491836 | Subjective well-being with antipsychotic treatment |
| Q55499428 | Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. |
| Q36557235 | Suboptimal treatment adherence in bipolar disorder: impact on clinical outcomes and functioning |
| Q24186517 | Supportive therapy for schizophrenia |
| Q24244072 | Supportive therapy for schizophrenia |
| Q92227663 | Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study |
| Q33334666 | The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area |
| Q45931497 | The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. |
| Q41436936 | The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale |
| Q47551032 | The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia |
| Q90697552 | The Role of Five Facets of Mindfulness in a Mindfulness-Based Psychoeducation Intervention for People With Recent-Onset Psychosis on Mental and Psychosocial Health Outcomes |
| Q38979325 | The SWITCH study: rationale and design of the trial. |
| Q34771556 | The accuracy of self-reported drug ingestion histories in emergency department patients |
| Q35187225 | The development and trial of a medication discontinuation program in the department of forensic psychiatry |
| Q51950804 | The effect of medication management training on community mental health nurse's clinical skills. |
| Q37228370 | The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia |
| Q38132709 | The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study |
| Q35096533 | The impact of cannabis use on clinical outcomes in recent onset psychosis. |
| Q38113746 | The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia |
| Q36460707 | The impact of subjective well-being under neuroleptic treatment on compliance and remission. |
| Q50156460 | The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia |
| Q47201221 | The new paradigm of recovery from schizophrenia: cultural conundrums of improvement without cure |
| Q48674168 | The predictive validity of subjective adherence measures in patients with schizophrenia. |
| Q34005474 | The relationship between insight and subjective experience in schizophrenia |
| Q35988494 | The relationships between patients' and caregivers' beliefs about the causes of schizophrenia and clinical outcomes in Latin American countries |
| Q37608912 | The role of the affective temperament in the treatment adherence in psychiatry |
| Q47598244 | The spectrum of subjective effects of antipsychotic medication |
| Q50619094 | To what extent psychiatric patients feel involved in decision making about their mental health care? Relationships with socio-demographic, clinical, and psychological variables. |
| Q24200966 | Training to recognise the early signs of recurrence in schizophrenia |
| Q35018988 | Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence |
| Q34592227 | Treatment non-adherence in affective disorders. |
| Q35103972 | Treatment of bipolar disorder in the Netherlands and concordance with treatment guidelines: study protocol of an observational, longitudinal study on naturalistic treatment of bipolar disorder in everyday clinical practice |
| Q40427430 | Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. |
| Q41859677 | Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the 'Tolerability and quality of life' (TOOL) questionnaire |
| Q37185607 | Validation of the Medication Adherence Rating Scale in homeless patients with schizophrenia: Results from the French Housing First experience. |
| Q34988776 | Validity of subjective versus objective quality of life assessment in people with schizophrenia |
| Q37427064 | Validity of the Control Preferences Scale in patients with emotional disorders. |
| Q92723437 | What Do Real Alcohol Outpatients Expect about Alcohol Transdermal Sensors? |
| Q37635197 | What are validated self-report adherence scales really measuring?: a systematic review. |
| Q47745528 | What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication |
| Q37691609 | Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness |
| Q34548527 | Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication |
| Q34752898 | Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapy |
| Q34604314 | Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial |
| Q75258563 | [The initial dysphoric reaction (IDR) to the first dose of neuroleptics] |
| Q79794007 | [The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients' expectations. A comparative study] |